Scancell advances melanoma Phase 3 plans and secures funding for proposed Nasdaq listing

Scancell is advancing its melanoma Phase 3 plans and has secured funding for a proposed Nasdaq listing, according to the company.

Detected & updated continuously · Source: Nebula